Inspect Point has partnered with Dyne Fire Protection Labs to connect sprinkler sampling and lab testing with inspection workflows.

Dyne Therapeutics started the new year with proof-of-concept clinical data for experimental genetic medicines addressing two rare muscle diseases—one of which has no FDA-approved treatments. Now the ...

Learn how laser scanning O-PTIR improves submicron analysis of microplastics and materials. The VERTEX NEO Ultra Bench-Top Vacuum FT-IR System is a fully automated vacuum FT-IR instrument that ...

Monday, Dyne Therapeutics Inc (NASDAQ:DYN) released clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its ongoing Phase 1/2 ...

Dyne Therapeutics, Inc. (DYN) is advancing the use of its FORCE platform to target skeletal muscle disorders. This would be with the use of modern oligonucleotide technology drugs like DYNE-101 and ...

The last time I wrote about Dyne Therapeutics (DYN) it was with respect to a Seeking Alpha article entitled "Dyne: H2 2024 Muscle Disease Data Could Boost Value". In this article, I noted about the ...